Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
New treatment options are critical for treatment-experienced HIV infected patients with drug
resistance. HIV entry inhibitors have been shown effective in patients with resistance to
other anti-HIV drugs. This study will test the safety and effectiveness of three different
doses of vicriviroc (formerly known as Schering D, SCH-D, or SCH 417690) in HIV infected
patients.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)